Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line.

Leukemia research - 1 Apr 2012

Xing Hongyun, Yang Xi, Liu Ting, Lin Juan, Chen Xiaoyi, Gong Yuping

Abstract excerpt

In this study, we established an imatinib resistant Ph+ acute lymphoblastic leukemia (ALL) cell line SUP-B15/RI in vitro and studied the mechanism of imatinib resistance. Our results showed that the BCR-ABL1 fusion gene and the mdr1 gene were 6.1 times and 1.7 times, respectively, as high as that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Fusion Proteins, bcr-abl
Share to Genes, MDR

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Imatinib Mesylate

Share to Immunoblotting

Share to Piperazines

Share to Precursor Cell Lymphoblastic Leukemia-Lymphoma

Share to Pyrimidines

Source

Identifiers

PMID: 22285507
DOI: 10.1016/j.leukres.2011.12.018

Genes

ABL1
BCR
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22285507-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line.PMID 22285507Read ↗

ABL kinase mutation and relapse in 4 pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia cases.Semantic proximity Read ↗

[Application of imatinib in BCR- ABL positive acute lymphoblastic leukemia treatment in the real world].Semantic proximity Read ↗

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.Semantic proximity Read ↗

A Convenient Cell Culture Model for CML Acquired Resistance Through BCR-ABL Mutations.Semantic proximity Read ↗

Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.Semantic proximity Read ↗

Effect of GINS2 on Proliferation and Apoptosis in Leukemic Cell LineSemantic proximity Read ↗

Analysis of gene expression profiles in an imatinib-resistant cell line, KCL22/SR.Semantic proximity Read ↗

Mechanisms, treatment strategies and predictive biomarkers of drug resistance in acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.